Welcome to our dedicated page for Outset Medical news (Ticker: OM), a resource for investors and traders seeking the latest updates and insights on Outset Medical stock.
Outset Medical, Inc. develops and commercializes dialysis technology centered on the Tablo Hemodialysis System, an FDA-cleared platform used across hospital and home care settings. Company news commonly covers Tablo adoption, consumables and service revenue, product gross margin, cash use, and financial guidance tied to the company’s medical technology business.
Recurring updates also include FDA matters for the Tablo platform, including 510(k) clearance for a next-generation system with cybersecurity, reliability, and connectivity enhancements. Governance and compensation announcements include board changes, executive appointments, and inducement equity grants under Nasdaq rules.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Outset Medical, Inc. (NASDAQ: OM), a pioneering medical technology firm, announced its participation in two upcoming investor conferences. The Bank of America Securities 2023 Health Care Conference is scheduled for May 9, 2023, at 1:40 PM PT, while the RBC Capital Markets Global Healthcare Conference will take place on May 17, 2023, at 5:00 AM PT. Live and archived webcasts of these events will be accessible via the Outset Investors' website.
Outset's flagship product, the Tablo Hemodialysis System, aims to streamline dialysis, making it more accessible and efficient for patients and providers. This innovative system integrates water purification and on-demand dialysate production, positioning it as a versatile solution for dialysis care.
Outset Medical, Inc. (NASDAQ: OM) has released five new abstracts at the National Kidney Foundation Spring Clinical Meetings highlighting innovations in home hemodialysis (HHD) and gender biases in nephrology. The studies demonstrate clinical and financial benefits of HHD, particularly in Hawaii, where Tablo was implemented effectively under challenging conditions. Key findings include a potential savings of $4.2M for Medicare Advantage plans through HHD expansion and estimated savings of $10.7M for providers using risk-based contracts. The research aims to enhance patient choice and access to dialysis options, addressing health disparities and gender equity issues in the field.
Outset Medical, Inc. (NASDAQ: OM) announced plans to release its financial results for Q1 2023 on May 3, 2023, after market close. CEO Leslie Trigg and CFO Nabeel Ahmed will host a conference call at 2:00 PM PT (5:00 PM ET) on the same day to discuss the results. The company focuses on revolutionizing dialysis with its Tablo® Hemodialysis System, which simplifies operational processes and enhances patient care. The system integrates water purification and dialysate production, serving as a mobile dialysis clinic. Interested parties can register online for the call and access a live or archived webcast on the Outset Investors page.
Outset Medical, Inc. (Nasdaq: OM), a leader in medical technology, announces participation in a fireside chat at the 43rd Annual Cowen Health Care Conference on Wednesday, March 8, 2023, at 9:50 a.m. PT / 12:50 p.m. ET. The event will be available via live and archived webcast on the Outset website.
Outset is known for its innovative Tablo Hemodialysis System, which simplifies dialysis by allowing for its use in various settings, from hospitals to homes. This FDA-cleared technology enhances patient care and operational efficiency, integrating water purification and on-demand dialysate production.
Outset Medical, Inc. (NASDAQ: OM) reported its financial results for Q4 and full year 2022. Q4 revenue was $32.0 million, up 14.0% year-over-year, and full-year revenue reached $115.4 million, marking a 12.4% increase. Gross margin for Q4 was 16.5%, improving significantly from 11.8% in Q4 2021, while full-year gross margin stood at 15.5%. The company increased its Tablo systems installation base by 54% year-over-year. Operating expenses rose to $45.1 million, with a net loss of $41.4 million for Q4. For 2023, Outset maintains revenue guidance of $140 to $150 million, projecting growth of approximately 22% to 30% over 2022.